Search Results - "Beck, Roy W"

Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials by Beck, Roy W, Bergenstal, Richard M, Riddlesworth, Tonya D, Kollman, Craig, Li, Zhaomian, Brown, Adam S, Close, Kelly L

“…This study evaluated the association of time in range (TIR) of 70-180 mg/dL (3.9-10 mmol/L) with the development or progression of retinopathy and development…”
Get full text

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry by Miller, Kellee M, Foster, Nicole C, Beck, Roy W, Bergenstal, Richard M, DuBose, Stephanie N, DiMeglio, Linda A, Maahs, David M, Tamborlane, William V

“…To examine the overall state of metabolic control and current use of advanced diabetes technologies in the U.S., we report recent data collected on individuals…”
Get full text

The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c by Beck, Roy W., Bergenstal, Richard M., Cheng, Peiyao, Kollman, Craig, Carlson, Anders L., Johnson, Mary L., Rodbard, David

“…Background: As the use of continuous glucose monitoring (CGM) increases, there is a need to better understand key metrics of time in range 70-180 mg/dL…”
Get full text

Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring by Bergenstal, Richard M, Beck, Roy W, Close, Kelly L, Grunberger, George, Sacks, David B, Kowalski, Aaron, Brown, Adam S, Heinemann, Lutz, Aleppo, Grazia, Ryan, Donna B, Riddlesworth, Tonya D, Cefalu, William T

“…While A1C is well established as an important risk marker for diabetes complications, with the increasing use of continuous glucose monitoring (CGM) to help…”
Get full text

Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study by Shah, Viral N, DuBose, Stephanie N, Li, Zoey, Beck, Roy W, Peters, Anne L, Weinstock, Ruth S, Kruger, Davida, Tansey, Michael, Sparling, David, Woerner, Stephanie, Vendrame, Francesco, Bergenstal, Richard, Tamborlane, William V, Watson, Sara E, Sherr, Jennifer

“…Abstract Context Use of continuous glucose monitoring (CGM) is increasing for insulin-requiring patients with diabetes. Although data on glycemic profiles of…”
Get full text

Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema by Elman, Michael J., MD, Bressler, Neil M., MD, Qin, Haijing, MS, Beck, Roy W., MD, PhD, Ferris, Frederick L., MD, Friedman, Scott M., MD, Glassman, Adam R., MS, Scott, Ingrid U., MD, MPH, Stockdale, Cynthia R., MSPH, Sun, Jennifer K., MD, MPH

“…Objective To report expanded 2-year follow-up of a previously reported randomized trial evaluating intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone…”
Get full text

Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema by Elman, Michael J., MD, Aiello, Lloyd Paul, MD, PhD, Beck, Roy W., MD, PhD, Bressler, Neil M., MD, Bressler, Susan B., MD, Edwards, Allison R., MS, Ferris, Frederick L., MD, Friedman, Scott M., MD, Glassman, Adam R., MS, Miller, Kellee M., MPH, Scott, Ingrid U., MD, MPH, Stockdale, Cynthia R., MSPH, Sun, Jennifer K., MD, MPH

“…Objective Evaluate intravitreal 0.5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of…”
Get full text

Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1c Levels in T1D Exchange Clinic Registry Participants by MILLER, Kellee M, BECK, Roy W, BERGENSTAL, Richard M, GOLAND, Robin S, HALLER, Michael J, MCGILL, Janet B, RODRIGUEZ, Henry, SIMMONS, Jill H, HIRSCH, Irl B

“…Despite substantial evidence of the benefit of frequent self-monitoring of blood glucose (SMBG) in type 1 diabetes, certain insurers limit the number of test…”
Get full text

Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels by Bergenstal, Richard M, Gal, Robin L, Connor, Crystal G, Gubitosi-Klug, Rose, Kruger, Davida, Olson, Beth A, Willi, Steven M, Aleppo, Grazia, Weinstock, Ruth S, Wood, Jamie, Rickels, Michael, DiMeglio, Linda A, Bethin, Kathleen E, Marcovina, Santica, Tassopoulos, Andreana, Lee, Sooji, Massaro, Elaine, Bzdick, Suzan, Ichihara, Brian, Markmann, Eileen, McGuigan, Paul, Woerner, Stephanie, Ecker, Michelle, Beck, Roy W

“…Debate exists as to whether the higher hemoglobin A1c (HbA1c) levels observed in black persons than in white persons are due to worse glycemic control or…”
Get full text

Real-time continuous glucose monitoring among participants in the T1D Exchange clinic registry by Wong, Jenise C, Foster, Nicole C, Maahs, David M, Raghinaru, Dan, Bergenstal, Richard M, Ahmann, Andrew J, Peters, Anne L, Bode, Bruce W, Aleppo, Grazia, Hirsch, Irl B, Kleis, Lora, Chase, H Peter, DuBose, Stephanie N, Miller, Kellee M, Beck, Roy W, Adi, Saleh

“…To assess the frequency of continuous glucose monitoring (CGM) device use, factors associated with its use, and the relationship of CGM with diabetes outcomes…”
Get full text

The Optimal Duration of a Run-In Period to Initiate Continuous Glucose Monitoring for a Randomized Trial by Raghinaru, Dan, Calhoun, Peter, Bergenstal, Richard M, Beck, Roy W

“…To determine the optimal duration of a run-in period for initiation of real-time continuous glucose monitoring (CGM) before the start of a randomized…”
Get more information

Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes by Davis, Asa K, DuBose, Stephanie N, Haller, Michael J, Miller, Kellee M, DiMeglio, Linda A, Bethin, Kathleen E, Goland, Robin S, Greenberg, Ellen M, Liljenquist, David R, Ahmann, Andrew J, Marcovina, Santica M, Peters, Anne L, Beck, Roy W, Greenbaum, Carla J

“…It is generally accepted that complete β-cell destruction eventually occurs in individuals with type 1 diabetes, which has implications for treatment…”
Get full text

Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis by Buckingham, Bruce A, Raghinaru, Dan, Cameron, Fraser, Bequette, B Wayne, Chase, H Peter, Maahs, David M, Slover, Robert, Wadwa, R Paul, Wilson, Darrell M, Ly, Trang, Aye, Tandy, Hramiak, Irene, Clarson, Cheril, Stein, Robert, Gallego, Patricia H, Lum, John, Sibayan, Judy, Kollman, Craig, Beck, Roy W

“…Nocturnal hypoglycemia can cause seizures and is a major impediment to tight glycemic control, especially in young children with type 1 diabetes. We conducted…”
Get full text

Concordance of Central Laboratory Hemoglobin A1c Measurements from Capillary Kits Compared to Venous Draws in the Insulin-Only Bionic Pancreas Pivotal Trial by Li, Zoey, Calhoun, Peter, Ruedy, Katrina J, Beck, Roy W

“…Capillary hemoglobin A1c (HbA1c) collection has grown in importance due to its convenience during situations such as the coronavirus disease 2019 (COVID-19)…”
Get more information

A Randomized Trial of a Home System to Reduce Nocturnal Hypoglycemia in Type 1 Diabetes by MAAHS, David M, CALHOUN, Peter, SLOVER, Robert, PAUL WADWA, R, WILSON, Darrell M, KOLLMAN, Craig, BECK, Roy W, BUCKINGHAM, Bruce A, PETER CHASE, H, HRAMIAK, Irene, LUM, John, CAMERON, Fraser, WAYNE BEQUETTE, B, AYE, Tandy, PAUL, Terri

“…Overnight hypoglycemia occurs frequently in individuals with type 1 diabetes and can result in loss of consciousness, seizure, or even death. We conducted an…”
Get full text

Glucose Management Indicator (GMI): Insights and Validation Using Guardian 3 and Navigator 2 Sensor Data by Leelarathna, Lalantha, Beck, Roy W, Bergenstal, Richard M, Thabit, Hood, Hovorka, Roman

Get full text

Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes by Rickels, Michael R, DuBose, Stephanie N, Toschi, Elena, Beck, Roy W, Verdejo, Alandra S, Wolpert, Howard, Cummins, Martin J, Newswanger, Brett, Riddell, Michael C

“…Patients with type 1 diabetes who do aerobic exercise often experience a drop in blood glucose concentration that can result in hypoglycemia. Current…”
Get full text

Short-term Outcomes After Very Low-Dose Intravitreous Bevacizumab for Retinopathy of Prematurity by Wallace, David K, Kraker, Raymond T, Freedman, Sharon F, Crouch, Eric R, Bhatt, Amit R, Hartnett, M Elizabeth, Yang, Michael B, Rogers, David L, Hutchinson, Amy K, VanderVeen, Deborah K, Haider, Kathryn M, Siatkowski, R Michael, Dean, Trevano W, Beck, Roy W, Repka, Michael X, Smith, Lois E, Good, William V, Kong, Lingkun, Cotter, Susan A, Holmes, Jonathan M

“…Intravitreous bevacizumab (0.25 mg to 0.625 mg) is commonly used to treat type 1 retinopathy of prematurity (ROP), but there are concerns about systemic…”
Get more information

Panretinal Photocoagulation for Proliferative Diabetic Retinopathy by Bressler, Neil M, Beck, Roy W, Ferris, Frederick L

“…Proliferative retinopathy develops in a 55-year-old man with type 2 diabetes. Panretinal photocoagulation, which causes reduced production of VEGF by…”
Get full text

Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP) by Bergenstal, Richard M, Ahmann, Andrew J, Bailey, Timothy, Beck, Roy W, Bissen, Joan, Buckingham, Bruce, Deeb, Larry, Dolin, Robert H, Garg, Satish K, Goland, Robin, Hirsch, Irl B, Klonoff, David C, Kruger, Davida F, Matfin, Glenn, Mazze, Roger S, Olson, Beth A, Parkin, Christopher, Peters, Anne, Powers, Margaret A, Rodriguez, Henry, Southerland, Phil, Strock, Ellie S, Tamborlane, William, Wesley, David M

“…Abstract Underutilization of glucose data and lack of easy and standardized glucose data collection, analysis, visualization, and guided clinical decision…”
Get more information